pocapavir

05/18/2018 - "While it was difficult to assess the relative contribution of each intervention, our case shows promise in the use of pocapavir for treatment of severe enteroviral infections. "
02/01/2017 - "Fifty-two of 93 pocapavir-treated subjects (56%) cleared virus in 2-18 days with no evidence of drug resistance, while 41 of 93 (44%) treated subjects experienced infection with resistant virus while in the isolation facility, 3 (3%) of whom were infected at baseline, before treatment initiation. "
01/01/2021 - "V-7404 may be combined with pocapavir (V-073), a capsid inhibitor, to treat these infections. "
01/01/2021 - "We describe the ongoing coordinated response to contain the infection, which included compassionate-use treatment with pocapavir."
01/15/2012 - "V-073 is in preclinical development for the treatment of poliovirus infections in the context of the worldwide polio eradication program. "

07/01/2017 - "Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment With Pocapavir."
07/01/2017 - "The literature regarding enterovirus myocarditis and pocapavir is briefly reviewed."
05/18/2018 - "We present the successful treatment of fulminant neonatal enteroviral myocarditis in a pair of monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir, an enteroviral capsid inhibitor. "
05/18/2018 - "Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir."

06/01/1997 - "On the basis of its in vitro and in vivo profiles, SCH 48973 represents a potential candidate for therapeutic intervention against enterovirus infections."
01/01/2018 - "Investigational agents such as the capsid inhibitors pleconaril and pocapavir show promise for treatment of neonatal enterovirus infections, and other investigational agents are being developed. "

01/01/2020 - "We describe the successful clearance of prolonged immunodeficiency-associated vaccine-derived type 3 poliovirus infection by pocapavir in an infant with underlying X-linked agammaglobulinemia."

01/15/2012 - "V-073 is in preclinical development for the treatment of poliovirus infections in the context of the worldwide polio eradication program. "
01/01/2020 - "Pocapavir exhibits antiviral activity against both polio and nonpolio enteroviruses. "
01/01/2019 - "As part of a 2011 randomised, blinded, placebo-controlled clinical trial of the experimental antiviral agent pocapavir (EudraCT 2011-004804-38), Swedish adults, aged 18-50 years, who had previously received four doses of inactivated polio vaccine (IPV) in childhood were challenged with a single dose of monovalent oral polio vaccine type 1 (mOPV1). "
08/01/2011 - "Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice."
08/01/2011 - "Immunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. "